Ignite Creation Date:
2025-12-25 @ 2:00 AM
Ignite Modification Date:
2025-12-26 @ 12:23 AM
Study NCT ID:
NCT04803994
Status:
RECRUITING
Last Update Posted:
2025-01-07
First Post:
2021-03-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-07-06
Start Date Type:
ACTUAL
Primary Completion Date:
2027-07
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-07
Completion Date Type:
ESTIMATED
First Submit Date:
2021-03-15
First Submit QC Date:
None
Study First Post Date:
2021-03-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-01-06
Last Update Post Date:
2025-01-07
Last Update Post Date Type:
ACTUAL